GlassScriptPhysician profile
John Patrick Willoughby
NPI 1962847533
$2,713.90
in general payments reported to CMS, 2019-2025
26 companies · $736 in 2025
The $736 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $60.14 · 2021: $214 · 2022: $640 · 2023: $611 · 2024: $338 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,684.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $812.62 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $407.30 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $208.27 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.59 | 2019-2025 | Spiriva Respimat, Ofev, Jascayd |
| Genzyme Corporation | $122.67 | 2019-2022 | |
| Insmed, INC. | $121.07 | 2022-2025 | Brinsupri, Arikayce |
| Mylan Specialty L.P. | $105.61 | 2019-2024 | Yupelri |
| Harmony Biosciences LLC | $98.15 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $67.32 | 2023-2024 | Opsumit, Uptravi |
| Ethicon INC. | $62.87 | 2024 | Monarch Platform |
| United Therapeutics Corporation | $62.59 | 2021-2023 | Tyvaso |
| Jazz Pharmaceuticals INC. | $55.61 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.22 | 2022-2025 | Glassia |
| Philips North America LLC | $53.88 | 2025 | Vest Therapy Und |
| Electromed, INC. | $51.82 | 2022-2025 | Smartvest |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $30.88 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $30.02 | 2022 | |
| Genentech USA, INC. | $29.43 | 2020-2023 | Xolair |
| Grifols USA, LLC | $22.51 | 2024 | Prolastin-C Liquid |
| Ani Pharmaceuticals, INC. | $21.23 | 2025 | Purified Cortrophin Gel |
| Shire North American Group INC | $16.92 | 2019 | |
| Melinta Therapeutics, LLC | $16.05 | 2019 | |
| Lilly USA, LLC | $14.45 | 2025 | Zepbound |
| Resmed Corp | $14.22 | 2023 | |
| Tactile Systems Technology INC | $13.32 | 2022 | |
| Merck Sharp & Dohme LLC | $13.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Willoughby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.